In Part 1 of this series, I touched on some of the unique considerations for advancing early-stage innovation beyond the academic setting. For this article, I’d like to dig deeper into the topic of university...
The honest truth? Deciding which early-stage technologies will be successful is really hard. This is even more the case when you add the challenges faced in a university setting. Although I’m currently on the investment...
Let me start by saying that the last two years have been a case study on focusing on priorities and filtering out noise. I’m fortunate to work in an area where it’s easy to see the long-term value of what we...
As discussed in my previous article “Portfolio Diversification During Times of Market Volatility,”[1] one of the few positive outcomes of the worldwide pandemic is the increasing recognition of the power of innovation...
VIC Technology Venture Development’s (www.victech.com) investment model sources promising life science innovation directly from universities across the nation, allocating funding to form startup companies and advance...
Update It is now March 2021, and nine months after writing this piece below, saying that things have evolved would be an understatement. Focusing on the positive progress made to date, we have three approved vaccines in...
As the recent pandemic has made all too clear, organizations need to proactively prepare for the realities of a dispersed workforce, which is especially true for investor groups such as venture capital and private...
For decades, only venture capital (VC) firms, and very rarely, angels were able to invest in start-up companies developing life science—therapeutics, medical devices, diagnostics, and related—innovation. Anyone doing...
Historically, innovative technologies discovered at universities, institutes and national labs have had two primary paths towards commercialization: (1) licensing to a large, pre-existing company; or, (2) licensing to...
FEATURED RESOURCES
